Click a link below to view the mailing archive as if it had been sent to you.
| 2024-03-29 00:15 | | FDA approves Gilead's Vemlidy drug for children with hepatitis B and more... |
| 2024-03-28 12:15 | | Gilead bets on Xilio cancer drug as biotech restructures and more... |
| 2024-03-28 00:15 | | Altimmune bails on hepatitis B after phase 2 data disappoint, quashing partnering plans and more... |
| 2024-03-27 12:15 | | Merck scores key FDA approval for pulmonary arterial hypertension drug Winrevair and more... |
| 2024-03-27 00:15 | | What the Supreme Court’s mifepristone hearing could mean for pharma and more... |
| 2024-03-26 12:15 | | Viking touts promising phase I data for weight-loss pill candidate and more... |
| 2024-03-26 00:15 | | In banner year, Lilly rewards CEO David Ricks with 24% boost in total pay to $26.6M and more... |
| 2024-03-25 12:15 | | Novo’s $1.1B Cardior buy continues expansion into heart disease and more... |
| 2024-03-25 00:15 | | FDA authorizes new drug to protect immune compromised from Covid-19 and more... |
| 2024-03-22 12:15 | | Medicare to cover Novo’s weight-loss drug Wegovy for patients with heart disease and more... |
| 2024-03-22 00:15 | | Top U.S. addiction researcher calls GLP-1 data for addiction ‘very, very exciting’ and more... |
| 2024-03-21 12:15 | | Galderma sets IPO price at top of range, or 53 Swiss francs a share and more... |
| 2024-03-21 00:15 | | Idorsia's Tryvio crosses FDA finish line, offering new mechanism to treat hypertension and more... |
| 2024-03-20 12:15 | | BMS racks up phase III win in liver cancer targeted by AstraZeneca and Roche and more... |
| 2024-03-20 00:15 | | COVID and Medicare payments spark remote patient monitoring boom and more... |
| 2024-03-19 12:15 | | AstraZeneca scoops up Fusion Pharmaceuticals in $2.4B radiopharma deal and more... |
| 2024-03-19 00:15 | | AstraZeneca Shows Lynparza Combo Could Address Unmet Endometrial Cancer Need and more... |
| 2024-03-18 12:15 | | Madrigal’s Rezdiffra Energizes MASH Space, Sets Bar for Future Therapies and more... |
| 2024-03-18 00:15 | | Despite early death concerns, FDA advisers back J&J and Legend's Carvykti and BMS' Abecma for earlier myeloma and more... |
| 2024-03-15 12:15 | | Moderna won’t advance US-backed Zika vaccine without more outside funding and more... |
| 2024-03-15 00:15 | | Madrigal wins FDA approval of first drug for MASH and more... |
| 2024-03-14 12:15 | | AstraZeneca boosts rare disease portfolio with $1.05B Amolyt acquisition and more... |
| 2024-03-14 00:15 | | FDA approves expanded use of Mirum's liver disease drug and more... |
| 2024-03-13 12:15 | | Lilly makes weight-loss drug Zepbound available through Amazon pharmacy and more... |
| 2024-03-13 00:15 | | AI to expand medtech portfolios, revenue streams: Moody’s and more... |
| 2024-03-12 12:15 | | FDA guidelines consider amyloid reduction 'reasonably likely' to predict Alzheimer's benefit and more... |
| 2024-03-12 00:15 | | Lilly's lebrikizumab, delayed at FDA, clears eczema in people with skin of color and more... |
| 2024-03-11 12:15 | | Sensorion's hearing loss drug reaches target in comeback story after phase 2 failure and more... |
| 2024-03-11 01:15 | | FDA clears use of Novo’s obesity drug to protect heart health and more... |
| 2024-03-11 00:15 | | FDA clears use of Novo’s obesity drug to protect heart health and more... |
| 2024-03-08 12:15 | | Lilly’s Donanemab Hit with Surprise Delay, Set to Face FDA Adcomm and more... |
| 2024-03-08 00:15 | | RSV monoclonal Beyfortus was 90% effective at preventing hospitalizations in children this winter and more... |
| 2024-03-07 12:15 | | Novo valuation surpasses Tesla on experimental obesity drug data and more... |
| 2024-03-06 12:15 | | Could pharma’s legal attack on the IRA succeed in killing price negotiations? and more... |
| 2024-03-06 00:15 | | Biopharma VC Funding Value Dropped Nearly 20% in Q4 2023: Pitchbook and more... |
| 2024-03-05 12:15 | | Novo kidney trial finds Ozempic cuts cardiac risks in diabetics and more... |
| 2024-03-05 00:15 | | Sandoz completes acquisition of ranibizumab biosimilar and more... |
| 2024-03-04 12:15 | | Bayer pays $310M to buy into BridgeBio heart drug and more... |
| 2024-03-04 00:15 | | A Behind-The-Counter Class Of Drugs Could Accelerate Rx-To-OTC Switches In U.S. and more... |
| 2024-03-01 12:15 | | ADC Market Will Remain Hot in Oncology, Reaching $30B by 2028: Report and more... |
| 2024-03-01 00:15 | | Pfizer fleshes out oncology strategy, targeting 8 blockbuster cancer drugs by 2030 and more... |
